TXG.NASDAQ10x Genomics, INC

Form 4: 10x Genomics Director Sridhar Kosaraju Reports Acquisition of Restricted Stock Units

Sentiment:

SEC Form 4 Filing

📋All filings for 10x Genomics, INC
🔒Login to Follow

Director Sridhar Kosaraju reports acquisition of restricted stock units and changes in beneficial ownership of Class A Common Stock.

Summary

  • On June 11, 2024, Sridhar Kosaraju, a director of 10x Genomics, Inc., reported changes in his beneficial ownership of the company's securities.
  • Kosaraju acquired 8,649 shares of Class A Common Stock through restricted stock units (RSUs) at a price of $0.
  • These RSUs vest quarterly, with 1/4th vesting on each quarterly anniversary from May 21, 2024, contingent upon continued service.
  • Following the transaction, Kosaraju directly owns 41,092 shares of Class A Common Stock.
  • Kosaraju also indirectly owns 3,000 shares of Class A Common Stock through the Kosaraju Family Trust dated June 21, 2014, where he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the holdings and transactions of key personnel.

Stakeholder Impact

  • The filing provides transparency to shareholders regarding insider transactions.

Key Dates

DateDescription
June 21, 2014Date of the Kosaraju Family Trust
May 21, 2024Starting date for quarterly vesting of RSUs
June 11, 2024Date of transaction: acquisition of RSUs
June 13, 2024Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.